TS
BBOT

Thomas Steyer’s BridgeBio Oncology BBOT Stock Holding History

Thomas Steyer’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-600,000
Closed -$6.39M – 167
2025
Q2 		$6.39M Hold
600,000
– – 0.03% 83
2025
Q1 		$6.78M Hold
600,000
– – 0.03% 77
2024
Q4 		$6.3M Hold
600,000
– – 0.03% 85
2024
Q3 		$6.27M Hold
600,000
– – 0.03% 92
2024
Q2 		$6.13M Hold
600,000
– – 0.03% 89
2024
Q1 		$6.21M Buy
+600,000
New +$6.21M 0.03% 99

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Thomas Steyer's BBOT Position: Q3 2025 in Review

Thomas Steyer sold out of BridgeBio Oncology (BBOT) in Q3 2025, closing a stake of 600,000 shares — an estimated $6.39M sold.

Thomas Steyer first reported a position in BBOT in Q1 2024 and held it in 6 quarters. The position peaked at $6.78M in Q1 2025. 42 funds tracked by Wall St. Rank hold BBOT as of Q3 2025.

  • Thomas Steyer reported no remaining BridgeBio Oncology position as of Q3 2025 after selling out during the quarter.
  • Thomas Steyer sold 600,000 BridgeBio Oncology shares in Q3 2025, an estimated $6.39M.
  • Thomas Steyer first reported a position in BridgeBio Oncology in Q1 2024 and held it in 6 quarters.
  • Thomas Steyer's BridgeBio Oncology position peaked at $6.78M in Q1 2025.
  • 42 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2025.

Based on Farallon Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.